Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | The addition of inotuzumab ozogamicin to hyper-CVAD + blinatumomab in patients with B-ALL

Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses results from a Phase II study evaluating the efficacy and safety of hyper-CVAD with sequential blinatumomab, with or without inotuzumab ozogamicin, in patients with newly diagnosed Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL). Overall, results demonstrated that the addition of inotuzumab ozogamicin to hyper-CVAD with sequential blinatumomab is safe and highly effective as frontline treatment of Ph- ALL. High rates of measurable residual disease (MRD) negativity were achieved and survival data was encouraging, including a high overall survival (OS) rate. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Novartis: Consultancy; Astellas: Research Funding; Takeda Oncology: Consultancy, Research Funding; Pfizer: Consultancy; Stemline Therapeutics: Research Funding; AstraZeneca: Consultancy; Amgen: Consultancy, Honoraria.